Nieuws en video's - EIGER BIOPHARMACEUTICALS INC.

Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a “stalking...

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan PR Newswire PALO ALTO, Calif., Jan. 18, 2024 Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone payment from AnGes Zokinvy approved in the U.S. (2020), 30 European countries (2022),...

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split PR Newswire PALO ALTO, Calif., Jan. 4, 2024 PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock...

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif., Nov. 9, 2023 Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Company's cash runway expected to extend into the third quarter of 2024 PALO ALTO, Calif. , Nov. 9, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc....

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta PR Newswire PALO ALTO, Calif., Sept. 12, 2023 PALO ALTO, Calif. , Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic...

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire PALO ALTO, Calif., Sept. 5, 2023 PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian , MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25 th Annual...

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif., Aug. 14, 2023 Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian , MD, PhD, MBA, appointed CEO PALO ALTO, Calif. , Aug. 14,...

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO PR Newswire PALO ALTO, Calif., June 29, 2023 Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024 David Apelian , MD, PhD, MBA, appointed CEO Live conference call and...

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow PR Newswire PALO ALTO, Calif., June 28, 2023 Company to host conference call and live webcast on Thursday, June 29 , at 8:30 am ET PALO ALTO, Calif. , June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company...

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif., May 11, 2023 Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of March 31, 2023 PALO ALTO, Calif. , May...

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) PR Newswire PALO ALTO, Calif., May 3, 2023 PALO ALTO, Calif. , May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance...

Thinking about buying stock in Bit Digital, Cipher Mining, Eiger Biopharmaceuticals, Eos Energy, or Bitfarms? PR Newswire NEW YORK, April 13, 2023 NEW YORK , April 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTBT, CIFR, EIGR, EOSE, and BITF. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BTBT:...

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments PR Newswire PALO ALTO, Calif., April 13, 2023 William G. Kachioff appointed as Chief Financial Officer James A. Vollins appointed as General Counsel, Chief Compliance Officer and Corporate Secretary PALO ALTO, Calif. , April 13, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV)...

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif., March 16, 2023 Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $98.9 million in Cash, Cash Equivalents, and Short-Term Debt Securities as...

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 PR Newswire PALO ALTO, Calif., Feb. 8, 2023 - Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events - Lambda reduced risk of hospitalization or emergency room visits by 51% (primary endpoint) - Lambda reduced risk of hospitalization by...

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm PR Newswire LOS ANGELES, Jan. 9, 2023 LOS ANGELES , Jan. 9, 2023 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharmaceuticals, Inc. ("Eiger" or "the Company") (NASDAQ: EIGR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and...

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Eiger securities between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Eiger Biopharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) in the United States District Court of Northern California on behalf of all persons and entities who purchased or otherwise acquired Eiger securities between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”). Investors have until...

EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Eiger investors who were adversely affected by alleged securities...

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) PR Newswire NEW YORK, Jan. 5, 2023 Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or...